Outcomes following cerebrospinal fluid shunting in high-grade glioma patients

Lorenzo Rinaldo, Desmond Brown, Giuseppe Lanzino, Ian F Parney

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE The clinical course of high-grade central nervous system gliomas is occasionally complicated by hydrocephalus. The risks of shunt placement and clinical outcome following CSF diversion in this population are not well defined. METHODS The authors retrospectively reviewed the outcomes of patients with pathologically confirmed WHO grade III or IV gliomas with shunt-treated hydrocephalus at their institution. Outcomes of patients in this cohort were compared with those of patients who underwent shunt treatment for normal pressure hydrocephalus (NPH). Hospital-reported outcomes in a national database for malignant primary brain tumor patients undergoing a ventricular shunt procedure were also reviewed. RESULTS Forty-one patients undergoing CSF shunting between 2001 and 2016 at the authors' institution were identified. Noncommunicating and communicating hydrocephalus occurred at similar rates (51.2% vs 48.8%). Symptomatic improvement after shunting was observed in 75.0% of patients. A major complication occurred in 17.1% of cases, with 2 patients suffering an intracranial hemorrhage. Prior administration of bevacizumab was significantly associated with the incidence of hemorrhage (p = 0.026). Three patients (7.3%) died during admission, and 8 (19.5%) died within 30 days of shunt placement. The presence of ependymal or leptomeningeal enhancement was more common in patients who died within 30 days (75.0% vs 11.1%, p = 0.001). Six patients (18.1%) required readmission to the hospital within 30 days of discharge. Revision surgery was necessary in 7 patients (17.1%). The median time from shunt placement to death was 150.5 days. In comparison with patients with NPH, shunt-treated high-grade glioma patients had increased in-hospital (7.3% vs 0.5%, p = 0.008) and 30-day (19.5% vs 0.8%, p < 0.001) mortality but no difference in the incidence of revision surgery (17.1% vs 17.5%, p = 0.947). Similarly, in the national Vizient Clinical Database Resource Manager, shunt-treated patients with malignant primary brain tumors had an increased length of stay (6.9 vs 3.5 days, p < 0.001), direct cost of admission ($15,755.80 vs $9871.50, p < 0.001), and 30-day readmission rates (20.6% vs 2.4%, p < 0.001) compared with patients without brain tumors who received a shunt for NPH. CONCLUSIONS Shunting can be an effective treatment for the symptoms of hydrocephalus in patients with high-grade gliomas. However, the authors' results suggest that this procedure carries a significant risk of complications in this patient population.

Original languageEnglish (US)
Pages (from-to)984-996
Number of pages13
JournalJournal of Neurosurgery
Volume129
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Glioma
Cerebrospinal Fluid
Hydrocephalus
Normal Pressure Hydrocephalus
Brain Neoplasms
Reoperation
Databases
Patient Readmission
Intracranial Hemorrhages
Incidence
Population
Length of Stay

Keywords

  • bevacizumab
  • communicating hydrocephalus
  • malignant gliomas
  • mortality
  • obstructive hydrocephalus
  • oncology
  • reoperation
  • ventriculoperitoneal shunt

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Outcomes following cerebrospinal fluid shunting in high-grade glioma patients. / Rinaldo, Lorenzo; Brown, Desmond; Lanzino, Giuseppe; Parney, Ian F.

In: Journal of Neurosurgery, Vol. 129, No. 4, 01.10.2018, p. 984-996.

Research output: Contribution to journalArticle

Rinaldo, Lorenzo ; Brown, Desmond ; Lanzino, Giuseppe ; Parney, Ian F. / Outcomes following cerebrospinal fluid shunting in high-grade glioma patients. In: Journal of Neurosurgery. 2018 ; Vol. 129, No. 4. pp. 984-996.
@article{0983324b65834e89b3347b4f29187440,
title = "Outcomes following cerebrospinal fluid shunting in high-grade glioma patients",
abstract = "OBJECTIVE The clinical course of high-grade central nervous system gliomas is occasionally complicated by hydrocephalus. The risks of shunt placement and clinical outcome following CSF diversion in this population are not well defined. METHODS The authors retrospectively reviewed the outcomes of patients with pathologically confirmed WHO grade III or IV gliomas with shunt-treated hydrocephalus at their institution. Outcomes of patients in this cohort were compared with those of patients who underwent shunt treatment for normal pressure hydrocephalus (NPH). Hospital-reported outcomes in a national database for malignant primary brain tumor patients undergoing a ventricular shunt procedure were also reviewed. RESULTS Forty-one patients undergoing CSF shunting between 2001 and 2016 at the authors' institution were identified. Noncommunicating and communicating hydrocephalus occurred at similar rates (51.2{\%} vs 48.8{\%}). Symptomatic improvement after shunting was observed in 75.0{\%} of patients. A major complication occurred in 17.1{\%} of cases, with 2 patients suffering an intracranial hemorrhage. Prior administration of bevacizumab was significantly associated with the incidence of hemorrhage (p = 0.026). Three patients (7.3{\%}) died during admission, and 8 (19.5{\%}) died within 30 days of shunt placement. The presence of ependymal or leptomeningeal enhancement was more common in patients who died within 30 days (75.0{\%} vs 11.1{\%}, p = 0.001). Six patients (18.1{\%}) required readmission to the hospital within 30 days of discharge. Revision surgery was necessary in 7 patients (17.1{\%}). The median time from shunt placement to death was 150.5 days. In comparison with patients with NPH, shunt-treated high-grade glioma patients had increased in-hospital (7.3{\%} vs 0.5{\%}, p = 0.008) and 30-day (19.5{\%} vs 0.8{\%}, p < 0.001) mortality but no difference in the incidence of revision surgery (17.1{\%} vs 17.5{\%}, p = 0.947). Similarly, in the national Vizient Clinical Database Resource Manager, shunt-treated patients with malignant primary brain tumors had an increased length of stay (6.9 vs 3.5 days, p < 0.001), direct cost of admission ($15,755.80 vs $9871.50, p < 0.001), and 30-day readmission rates (20.6{\%} vs 2.4{\%}, p < 0.001) compared with patients without brain tumors who received a shunt for NPH. CONCLUSIONS Shunting can be an effective treatment for the symptoms of hydrocephalus in patients with high-grade gliomas. However, the authors' results suggest that this procedure carries a significant risk of complications in this patient population.",
keywords = "bevacizumab, communicating hydrocephalus, malignant gliomas, mortality, obstructive hydrocephalus, oncology, reoperation, ventriculoperitoneal shunt",
author = "Lorenzo Rinaldo and Desmond Brown and Giuseppe Lanzino and Parney, {Ian F}",
year = "2018",
month = "10",
day = "1",
doi = "10.3171/2017.6.JNS17859",
language = "English (US)",
volume = "129",
pages = "984--996",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Outcomes following cerebrospinal fluid shunting in high-grade glioma patients

AU - Rinaldo, Lorenzo

AU - Brown, Desmond

AU - Lanzino, Giuseppe

AU - Parney, Ian F

PY - 2018/10/1

Y1 - 2018/10/1

N2 - OBJECTIVE The clinical course of high-grade central nervous system gliomas is occasionally complicated by hydrocephalus. The risks of shunt placement and clinical outcome following CSF diversion in this population are not well defined. METHODS The authors retrospectively reviewed the outcomes of patients with pathologically confirmed WHO grade III or IV gliomas with shunt-treated hydrocephalus at their institution. Outcomes of patients in this cohort were compared with those of patients who underwent shunt treatment for normal pressure hydrocephalus (NPH). Hospital-reported outcomes in a national database for malignant primary brain tumor patients undergoing a ventricular shunt procedure were also reviewed. RESULTS Forty-one patients undergoing CSF shunting between 2001 and 2016 at the authors' institution were identified. Noncommunicating and communicating hydrocephalus occurred at similar rates (51.2% vs 48.8%). Symptomatic improvement after shunting was observed in 75.0% of patients. A major complication occurred in 17.1% of cases, with 2 patients suffering an intracranial hemorrhage. Prior administration of bevacizumab was significantly associated with the incidence of hemorrhage (p = 0.026). Three patients (7.3%) died during admission, and 8 (19.5%) died within 30 days of shunt placement. The presence of ependymal or leptomeningeal enhancement was more common in patients who died within 30 days (75.0% vs 11.1%, p = 0.001). Six patients (18.1%) required readmission to the hospital within 30 days of discharge. Revision surgery was necessary in 7 patients (17.1%). The median time from shunt placement to death was 150.5 days. In comparison with patients with NPH, shunt-treated high-grade glioma patients had increased in-hospital (7.3% vs 0.5%, p = 0.008) and 30-day (19.5% vs 0.8%, p < 0.001) mortality but no difference in the incidence of revision surgery (17.1% vs 17.5%, p = 0.947). Similarly, in the national Vizient Clinical Database Resource Manager, shunt-treated patients with malignant primary brain tumors had an increased length of stay (6.9 vs 3.5 days, p < 0.001), direct cost of admission ($15,755.80 vs $9871.50, p < 0.001), and 30-day readmission rates (20.6% vs 2.4%, p < 0.001) compared with patients without brain tumors who received a shunt for NPH. CONCLUSIONS Shunting can be an effective treatment for the symptoms of hydrocephalus in patients with high-grade gliomas. However, the authors' results suggest that this procedure carries a significant risk of complications in this patient population.

AB - OBJECTIVE The clinical course of high-grade central nervous system gliomas is occasionally complicated by hydrocephalus. The risks of shunt placement and clinical outcome following CSF diversion in this population are not well defined. METHODS The authors retrospectively reviewed the outcomes of patients with pathologically confirmed WHO grade III or IV gliomas with shunt-treated hydrocephalus at their institution. Outcomes of patients in this cohort were compared with those of patients who underwent shunt treatment for normal pressure hydrocephalus (NPH). Hospital-reported outcomes in a national database for malignant primary brain tumor patients undergoing a ventricular shunt procedure were also reviewed. RESULTS Forty-one patients undergoing CSF shunting between 2001 and 2016 at the authors' institution were identified. Noncommunicating and communicating hydrocephalus occurred at similar rates (51.2% vs 48.8%). Symptomatic improvement after shunting was observed in 75.0% of patients. A major complication occurred in 17.1% of cases, with 2 patients suffering an intracranial hemorrhage. Prior administration of bevacizumab was significantly associated with the incidence of hemorrhage (p = 0.026). Three patients (7.3%) died during admission, and 8 (19.5%) died within 30 days of shunt placement. The presence of ependymal or leptomeningeal enhancement was more common in patients who died within 30 days (75.0% vs 11.1%, p = 0.001). Six patients (18.1%) required readmission to the hospital within 30 days of discharge. Revision surgery was necessary in 7 patients (17.1%). The median time from shunt placement to death was 150.5 days. In comparison with patients with NPH, shunt-treated high-grade glioma patients had increased in-hospital (7.3% vs 0.5%, p = 0.008) and 30-day (19.5% vs 0.8%, p < 0.001) mortality but no difference in the incidence of revision surgery (17.1% vs 17.5%, p = 0.947). Similarly, in the national Vizient Clinical Database Resource Manager, shunt-treated patients with malignant primary brain tumors had an increased length of stay (6.9 vs 3.5 days, p < 0.001), direct cost of admission ($15,755.80 vs $9871.50, p < 0.001), and 30-day readmission rates (20.6% vs 2.4%, p < 0.001) compared with patients without brain tumors who received a shunt for NPH. CONCLUSIONS Shunting can be an effective treatment for the symptoms of hydrocephalus in patients with high-grade gliomas. However, the authors' results suggest that this procedure carries a significant risk of complications in this patient population.

KW - bevacizumab

KW - communicating hydrocephalus

KW - malignant gliomas

KW - mortality

KW - obstructive hydrocephalus

KW - oncology

KW - reoperation

KW - ventriculoperitoneal shunt

UR - http://www.scopus.com/inward/record.url?scp=85052066217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052066217&partnerID=8YFLogxK

U2 - 10.3171/2017.6.JNS17859

DO - 10.3171/2017.6.JNS17859

M3 - Article

C2 - 29271709

AN - SCOPUS:85052066217

VL - 129

SP - 984

EP - 996

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 4

ER -